Equillium, Inc. (EQ)

Equillium's stock price has increased by 168.29% in the past six months and 104.12% over the past year. In August 2025, Equillium announced a securities purchase agreement providing up to $50 million to advance EQ504. In April 2025, the FDA declined to grant Breakthrough Therapy designation or support an Accelerated Approval pathway for itolizumab for aGVHD. In March 2025, Equillium reported its Q4 and full-year 2024 financial results, with the Phase 3 EQUATOR study for itolizumab in aGVHD not meeting its primary endpoint but demonstrating benefits in longer-term outcomes. The company reported a net loss of $8.1 million for the full year 2024 and indicated its cash could fund operations into Q3 2025.

Equillium's products are still in development, so there is no established demand seasonality. The nature of the diseases it aims to treat suggests that once approved, demand for its therapies would likely be consistent rather than seasonal.

Equillium, Inc. is a clinical-stage biotechnology company focused on developing innovative therapeutics for severe autoimmune and inflammatory disorders. The company's pipeline includes Itolizumab (EQ001), EQ101, EQ302, and EQ504. Itolizumab is in Phase 3 clinical trials for acute graft-versus-host disease (aGVHD), has completed Phase 1b clinical trials for systemic lupus erythematosus and lupus nephritis, and is in Phase 2 clinical trials for ulcerative colitis. EQ101 has completed Phase 1/2 trials for cutaneous T cell lymphoma. EQ302 is in preclinical development, but activities are paused pending funding or partnering. EQ504 has a Phase 1 clinical study planned for mid-2026.

Equillium, Inc. is headquartered in La Jolla, California, United States, with operations extending to Australia, the US, and New Zealand.

Equillium's brand reputation has been influenced by clinical development progress and regulatory interactions. The FDA's decision to decline Breakthrough Therapy designation for itolizumab for aGVHD could be perceived negatively. However, positive longer-term outcomes in the Phase 3 EQUATOR study and positive Phase 2 results for itolizumab in ulcerative colitis could bolster its reputation. The successful securing of up to $50 million in financing also indicates investor confidence.

Individual investors collectively hold the largest stake, with 30% ownership. Institutional investors hold between 25% and 46.7% of the company's stock. Major institutional owners and shareholders include ADAR1 Capital Management, LLC, Adage Capital Partners Gp, L.l.c., Decheng Capital LLC, Woodline Partners LP, Balyasny Asset Management Llc, StemPoint Capital LP, Takeda Pharmaceutical Co Ltd, Vanguard Group Inc, Renaissance Technologies Llc, VTSMX - Vanguard Total Stock Market Index Fund Investor Shares, Biocon Ltd., and State Street Corp.